Senti Bioscience Stock Price, News & Analysis

Senti Biosciences (SNTI) presented promising preclinical data on its SENTI-202 CAR-NK cell therapy at the AACR Annual Meeting. This therapy targets CD33 and/or FLT3 for treating hematologic malignancies, showing enhanced cytotoxic activity and safety in in vitro and in vivo models. The company aims to submit an IND application by the second half of 2023, focusing on relapsed/refractory patients. Data on SENTI-301A further demonstrated CAR-NK cells' ability to improve persistence and anti-tumor efficacy. Overall, Senti Bio aims to revolutionize treatment for both liquid and solid tumors through its innovative gene circuit technology.

Senti Biosciences, Inc. (Nasdaq: SNTI), a biotechnology innovator in cell and gene therapies, announced its participation in several upcoming investor conferences. The events include:

• Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
  Date: April 24, 2023, 10:00 a.m. ET (Virtual)
• Bank of America 2023 Global Healthcare Conference
  Date: May 10, 2023 (Las Vegas, NV)
• The JMP Securities Life Sciences Conference
  Date: May 15, 2023, 2:30 p.m. ET (New York, NY)

Live webcasts will be available via the Senti Bio website, with archived replays accessible for 90 days after each event. Senti Bio aims to pioneer smarter therapies through its synthetic biology platform and proprietary Gene Circuit technology to enhance treatment precision in complex diseases.

Senti Biosciences (SNTI) reported significant advancements in its therapeutic pipeline, particularly with the upcoming IND application for SENTI-202 aimed at treating hematologic malignancies including AML and MDS, scheduled for submission in H2 2023. The company holds $98.6 million in cash and equivalents as of December 31, 2022, ensuring operational funding through at least Q1 2024. Research and development expenses increased to $34.1 million in 2022, compounded by substantial general and administrative costs of $40.8 million. The company recorded a net loss of $58.2 million for the year. Overall, Senti is positioned for ongoing growth with its innovative Gene Circuit technology.

Senti Biosciences (Nasdaq: SNTI) announces acceptance of three abstracts for presentation at the AACR Annual Meeting, scheduled for April 14-19, 2023, in Orlando, Florida. The abstracts focus on Senti Bio's proprietary CAR-NK cell therapies targeting hematologic malignancies and solid tumors. Notably, SENTI-202 is a logic gated CAR-NK cell therapy aimed at treating CD33/FLT3+ malignancies, with an IND submission planned for the second half of 2023. Additionally, data will showcase the enhanced capabilities of CAR-NK therapies through the incorporation of calibrated release IL-15. The presentations underline Senti Bio's innovative approaches and strategic partnerships to address oncology challenges.

Senti Biosciences, Inc. (Nasdaq: SNTI) announced the grant of stock options to 13 new employees, totaling 309,000 shares at an exercise price of $1.81, effective February 1, 2023. This action aligns with NASDAQ Listing Rule 5635(c)(4) and the 2022 Inducement Equity Plan. Senti Bio aims to innovate cell and gene therapies using its proprietary Gene Circuit technology, targeting complex diseases. Its lead candidate, SENTI-202, focuses on hematologic malignancies, while SENTI-401 addresses colorectal cancer and other CEA-positive cancers. The company has partnerships with Spark Therapeutics and BlueRock Therapeutics to enhance its capabilities.

Senti Biosciences, Inc. (Nasdaq: SNTI) announced its Co-Founder and CEO, Tim Lu, MD, PhD, will present at the virtual SVB Securities Global Biopharma Conference from February 13-16, 2023. Lu’s presentation is scheduled for February 16 at 3:40 PM ET. A live webcast can be accessed at this link and will be available for 90 days post-event. Senti Bio is advancing its Gene Circuit technology platform, targeting challenging cancers with its lead candidate, SENTI-202, and other programs like SENTI-401. For more details, visit Senti Bio's website.

Senti Biosciences (Nasdaq: SNTI) has announced a strategic focus on its lead oncology candidates, SENTI-202 and SENTI-401, for treating acute myeloid leukemia (AML) and colorectal cancer, respectively. The company is on track for an IND filing of SENTI-202 in the second half of 2023 and has extended its cash runway through at least Q1 2024. While the development of SENTI-301A for hepatocellular carcinoma (HCC) is deprioritized, Senti Bio aims to establish partnerships for its clinical progression. The advancements in gene circuit technology are expected to enhance therapy precision and effectiveness.